Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering
Analysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuViva
Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor
Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation
Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings
Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial
Guided Therapeutics Makes Initial Shipment to New Chinese Distribution Partner Hangzhou Dongye Medical Technology, Ltd.
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
Guided Therapeutics Receives $100,000 from SMI’s Investment Partners to Continue Commercialization Process of LuViva in China
Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables
Guided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in China
Guided Therapeutics’ Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites With Better Than Expected Results
Guided Therapeutics Reports Q3 EPS ($0.02) vs. Prior Year Quarter ($0.04)
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
